Skip to main content
43 search results for:

Axitinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 26-07-2022 | Renal cell carcinoma | News | Article

    KEYNOTE-426 QoL data further support pembrolizumab–axitinib in RCC

    Combination therapy with pembrolizumab plus axitinib results in similar health-related quality of life outcomes to that with sunitinib monotherapy for untreated advanced renal cell carcinoma, KEYNOTE-426 study data show.

  2. play
    25-02-2022 | ASCO GU 2022 | Conference coverage | Video

    Neoadjuvant avelumab plus axitinib active in high-risk RCC

    Axel Bex outlines the reasoning behind the choice of tumor response as the primary endpoint for the NeoAvAx study of avelumab plus axitinib in the neoadjuvant high-risk renal cell carcinoma setting, and discusses the next steps.

  3. 11-03-2022 | Renal cell carcinoma | News | Article

    Troponin T linked to MACE risk in RCC patients receiving avelumab–axitinib

    High baseline levels of troponin T may increase the risk for major adverse cardiovascular events among advanced renal cell carcinoma patients receiving combination treatment with avelumab plus axitinib, suggest data from the JAVELIN Renal 101 trial.

  4. 20-02-2022 | ASCO GU 2022 | Conference coverage | Article

    ​​​​​​​Combined nivolumab, axitinib treatment elicits good response in metastatic RCC

    Combination treatment with nivolumab plus axitinib has achieved a high response rate in patients with metastatic renal cell carcinoma enrolled in a phase 1/2 trial.

  5. 22-02-2022 | ASCO GU 2022 | Conference coverage | Article

    ​​​​​​​NeoAvAx shows promise of neoadjuvant avelumab–axitinib for localized high-risk RCC

    The NeoAvAx trial has demonstrated encouraging response and disease-free survival after neoadjuvant treatment with avelumab plus axitinib in people with locally advanced renal cell carcinoma at high risk for relapse after nephrectomy.

  6. play
    19-02-2021 | ASCO GU 2021 | Conference coverage | Video

    TIVO-3 results point to tivozanib activity after RCC progression on axitinib

    Brian Rini describes an analysis of the TIVO-3 advanced renal cell carcinoma trial suggesting that tivozanib offers better outcomes than sorafenib even in patients who have previously received axitinib.

  7. 09-06-2020 | ASCO 2020 | News | Article

    KEYNOTE-426 update ‘continues to support’ pembrolizumab plus axitinib

    For patients with treatment-naïve advanced renal cell carcinoma, pembrolizumab plus axitinib offers superior overall survival to sunitinib, confirms an updated analysis from the KEYNOTE-426 trial. This independent news story was supported by an educational grant from Pfizer and Merck KGaA

  8. 08-10-2019 | Renal cell carcinoma | News | Article

    JAVELIN Renal 101 subanalyses add to evidence for avelumab plus axitinib

    Findings from the JAVELIN Renal 101 trial of patients with advanced renal cell carcinoma suggest front-line use of avelumab plus axitinib is superior to sunitinib for patients with sarcomatoid histology and for those who did not undergo upfront cytoreductive nephrectomy.

  9. 09-06-2019 | Renal cell carcinoma | News | Article

    KEYNOTE-426 subgroup analyses confirm pembrolizumab–axitinib efficacy

    Research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, adds support for use of pembrolizumab plus axitinib  as a first-line treatment for patients with metastatic renal cell carcinoma.

  10. 17-05-2019 | FDA | News | Article
    approvalsWatch

    USA approves first-line avelumab–axitinib for advanced RCC

    medwireNews : US patients with treatment-naïve advanced renal cell carcinoma (RCC) may now be given the PD-L1 inhibitor avelumab in combination with the VEGFR inhibitor axitinib.

  11. 19-02-2019 | Renal cell carcinoma | News | Article
    ASCO GU 2019

    Pembrolizumab–axitinib boosts untreated advanced RCC survival

    Overall survival is significantly improved with the first-line combination of pembrolizumab and axitinib relative to sunitinib in patients with advanced renal cell carcinoma, shows the KEYNOTE-426 trial.

  12. 29-04-2019 | FDA | News | Article
    approvalsWatch

    FDA approves first-line pembrolizumab–axitinib for advanced RCC

    The recommended dosage is pembrolizumab 200 mg every 3 weeks alongside axitinib 5 mg twice daily.

  13. 27-10-2018 | Renal cell carcinoma | Teaser
    medwireNews editor's pick

    First-line avelumab–axitinib outperforms sunitinib in advanced RCC

    Results of the JAVELIN Renal 101 trial indicate that patients with a new diagnosis of advanced renal cell carcinoma have better outcomes when treated with the combination of avelumab and axitinib than with sunitinib.

  14. 26-10-2018 | Renal cell carcinoma | News | Article

    First-line avelumab–axitinib outperforms sunitinib in advanced RCC

    Results of the JAVELIN Renal 101 trial indicate that patients with a new diagnosis of advanced renal cell carcinoma have better outcomes when treated with the combination of avelumab and axitinib than with sunitinib.

  15. 07-10-2017 | Glioblastoma multiforme | Article

    Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma

    After the early promise shown by the small molecule tyrosine kinase inhibitor axitinib in patients with recurrent glioblastoma in a randomized phase II trial, this report details further investigation following amendment and continuation of the trial. Duerinck J et al. J Neurooncol 2017. doi:10.1007/s11060-017-2629-z

  16. 23-03-2018 | Renal cell carcinoma | News | Article

    Promising early data reported for avelumab plus axitinib in advanced RCC

    Results from the JAVELIN Renal 100 study suggest that avelumab plus axitinib is a tolerable combination, with encouraging antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.

  17. 14-11-2022 | Renal cell carcinoma | News | Article

    Second-line metastatic RCC outcomes similar regardless of first-line immunotherapy combo partner

    All patients in the dual IO group received nivolumab plus ipilimumab, while the most common regimens in the TKI plus IO group were axitinib plus pembrolizumab (34%), lenvatinib plus pembrolizumab (29%), and axitinib plus avelumab (25%).

  18. 16-12-2021 | Immunotherapy | News | Article

    HLA-A*03 shows potential as a biomarker for ICI response

    And a similar pattern was observed for the 720 participants of the JAVELIN Renal 101 trial that compared avelumab plus axitinib with sunitinib.

  19. 10-05-2021 | Adis Journal Club | Article
    Targeted Oncology

    Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study

    Results We identified 51,836 adverse event reports of sunitinib, pazopanib, axitinib, cabozantinib, and lenvatinib in the full database [36% women; median age 65 years (range 57–73)].

  20. 04-05-2021 | Lung and thoracic tumors | At a glance | Article

    At a glance: The JAVELIN lung cancer trials

    JAVELIN Medley VEGF: Ongoing   Phase 2 Patient population: Locally advanced or metastatic NSCLC or urothelial cancer Treatment: Avelumab 800 mg every 2 weeks plus axitinib 5 mg twice a day Sponsor: Pfizer https://clinicaltrials.gov/ct2/show/NCT03472560 Results presented in a poster  at The Society for Immunotherapy of Cancer’s 2020 annual meeting showed a confirmed ORR of 31.7% in the NSCLC cohort, which comprised individuals with no activating EGFR , ALK , or ROS1 alterations who had received at least one prior platinum-containing therapy but no more than two prior lines of systemic therapy.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.